Candid Therapeutics is focused on developing innovative treatments for autoimmune diseases through its advanced pipeline of bispecific antibodies. The company is working on two primary candidates: CND106 and CND261. CND106 is a BCMAxCD3 bispecific antibody that targets and eliminates later-stage B-cells responsible for producing harmful autoantibodies, particularly in conditions like myasthenia gravis. This approach aims to provide deeper and more effective responses compared to existing therapies, such as Anti-FcRn treatments. CND106 has successfully completed a Phase 1 dose escalation study in oncology and is now being repurposed for autoimmune applications.

CND261, on the other hand, is a CD20xCD3 bispecific antibody designed to engage a wide range of B-cell subtypes, from pro B-cells to plasma cells. This technology builds on the success of existing CD20-based therapies but aims to enhance efficacy through its unique T-cell engager mechanism. Like CND106, CND261 has also completed a Phase 1 dose escalation study in oncology and is being developed to meet the unmet needs in various autoimmune diseases, including rheumatoid arthritis. Together, these therapies represent Candid Therapeutics' commitment to revolutionizing treatment paradigms in the field of autoimmune disorders.

United States

Developing innovative therapeutics to materially improve the lives of patients. We strive to be transparent and open in our goals, plans, and progress.

Candid Therapeutics

Company Details